48 related articles for article (PubMed ID: 30553736)
1. Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug.
Liu W; Liang L; Zhao L; Tan H; Wu J; Qin Q; Gou X; Sun X
Bioorg Med Chem Lett; 2019 Feb; 29(3):487-490. PubMed ID: 30553736
[TBL] [Abstract][Full Text] [Related]
2. Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy.
Santra S; Kaittanis C; Santiesteban OJ; Perez JM
J Am Chem Soc; 2011 Oct; 133(41):16680-8. PubMed ID: 21910482
[TBL] [Abstract][Full Text] [Related]
3. Diselenide-Bridged Doxorubicin Dimeric Prodrug: Synthesis and Redox-Triggered Drug Release.
Hu Y; Liu P
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675530
[TBL] [Abstract][Full Text] [Related]
4. Anticancer nano-prodrugs with drug release triggered by intracellular dissolution and hydrogen peroxide response.
Shibata A; Koseki Y; Tanita K; Kitajima S; Oka K; Maruoka K; Suzuki R; Thi Ngoc Dao A; Kasai H
Chem Commun (Camb); 2024 Jun; 60(50):6427-6430. PubMed ID: 38829169
[TBL] [Abstract][Full Text] [Related]
5. Sequential drug delivery by injectable macroporous hydrogels for combined photodynamic-chemotherapy.
Zhong Y; Zhang L; Sun S; Zhou Z; Ma Y; Hong H; Yang D
J Nanobiotechnology; 2021 Oct; 19(1):333. PubMed ID: 34688292
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Prodrug Capable of Mitochondria-Targeting, Light-Triggered Release, and Fluorescence Monitoring.
Jung YL; Yang YJ; Shil A; Sarkar S; Ahn KH
ACS Appl Bio Mater; 2024 Jun; 7(6):3991-3996. PubMed ID: 38835291
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs.
Pettit GR; Rosenberg HJ; Dixon R; Knight JC; Hamel E; Chapuis JC; Pettit RK; Hogan F; Sumner B; Ain KB; Trickey-Platt B
J Nat Prod; 2012 Mar; 75(3):385-93. PubMed ID: 22324723
[TBL] [Abstract][Full Text] [Related]
8. Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
Winn BA; Devkota L; Kuch B; MacDonough MT; Strecker TE; Wang Y; Shi Z; Gerberich JL; Mondal D; Ramirez AJ; Hamel E; Chaplin DJ; Davis P; Mason RP; Trawick ML; Pinney KG
J Nat Prod; 2020 Apr; 83(4):937-954. PubMed ID: 32196334
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic agents. 552. Oxidation of combretastatin A-1: trapping the o-quinone intermediate considered the metabolic product of the corresponding phosphate prodrug.
Pettit GR; Thornhill AJ; Moser BR; Hogan F
J Nat Prod; 2008 Sep; 71(9):1561-3. PubMed ID: 18729517
[TBL] [Abstract][Full Text] [Related]
10. Mineralization of pH-Sensitive Doxorubicin Prodrug in ZIF-8 to Enable Targeted Delivery to Solid Tumors.
Yan J; Liu C; Wu Q; Zhou J; Xu X; Zhang L; Wang D; Yang F; Zhang H
Anal Chem; 2020 Aug; 92(16):11453-11461. PubMed ID: 32664723
[TBL] [Abstract][Full Text] [Related]
11. Selective activation of prodrugs in breast cancer using metabolic glycoengineering and the tetrazine ligation bioorthogonal reaction.
Mitry MMA; Dallas ML; Boateng SY; Greco F; Osborn HMI
Bioorg Chem; 2024 Jun; 147():107304. PubMed ID: 38643563
[TBL] [Abstract][Full Text] [Related]
12. Design and preparation of pH-sensitive cytotoxic liposomal formulations containing antitumor colchicine analogues for target release.
Shchegravina ES; Tretiakova DS; Sitdikova AR; Usova SD; Boldyrev IA; Alekseeva AS; Svirshchevskaya EV; Vodovozova EL; Fedorov AY
J Liposome Res; 2024 Sep; 34(3):399-410. PubMed ID: 37867342
[TBL] [Abstract][Full Text] [Related]
13. A chiral trimethyl lock based on the
Venturi S; Chiaradonna F; Gatti FG; La Ferla B; Palorini R; Zerbato B
Chem Commun (Camb); 2024 Jun; 60(51):6524-6527. PubMed ID: 38836387
[TBL] [Abstract][Full Text] [Related]
14. Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2.
Pettit GR; Quistorf PD; Fry JA; Herald DL; Hamel E; Chapuis JC
J Nat Prod; 2009 May; 72(5):876-83. PubMed ID: 20161135
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of antisense oligonucleotides prodrug with G-quadruplex assembly and lysosome escape capabilities for oncotherapy.
Chen Z; Zhang Z; Liu S; Xiao Z; Luo Y; Pan X; Feng X; Xu L
Bioorg Chem; 2024 Jul; 148():107475. PubMed ID: 38772293
[TBL] [Abstract][Full Text] [Related]
16. Phenylboronic Acid Modification Augments the Lysosome Escape and Antitumor Efficacy of a Cylindrical Polymer Brush-Based Prodrug.
Wang R; Yin C; Liu C; Sun Y; Xiao P; Li J; Yang S; Wu W; Jiang X
J Am Chem Soc; 2021 Dec; 143(49):20927-20938. PubMed ID: 34855390
[TBL] [Abstract][Full Text] [Related]
17. Design of a prodrug photocage for cancer cells detection and anticancer drug release.
Shao Q; Zhang F; Li C; Yang Y; Liu S; Chen G; Fan B
Talanta; 2024 Jul; 274():126002. PubMed ID: 38613948
[TBL] [Abstract][Full Text] [Related]
18. Visible light-activated prodrug system with a novel heavy-atom-free photosensitizer.
Yang S; Wang L; Loredo A; Wang S; Ada N; Xiao H
Bioorg Med Chem Lett; 2023 Jul; 91():129365. PubMed ID: 37290494
[TBL] [Abstract][Full Text] [Related]
19. Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death.
Sarkar A; Novohradsky V; Maji M; Babu T; Markova L; Kostrhunova H; Kasparkova J; Gandin V; Brabec V; Gibson D
Angew Chem Int Ed Engl; 2023 Oct; 62(42):e202310774. PubMed ID: 37646232
[TBL] [Abstract][Full Text] [Related]
20. In vitro results with minimal blood toxicity of a combretastatin A4 analogue.
Chagas C; Mansano JV; da Silva EB; Petri G; da Costa Aguiar Alves Reis B; Schumacher ML; Haddad PS; Pereira EC; Britos TN; Barreiro EJ; Lima LM; Ferreira FF; Fonseca FLA
Invest New Drugs; 2024 Jun; 42(3):318-325. PubMed ID: 38758478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
